Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 704

Results For "RI"

11153 News Found

Govt.  setting up of Ayush - ICMR Advanced Centre for AI-ACIHR at select AIIMS
News | March 04, 2024

Govt. setting up of Ayush - ICMR Advanced Centre for AI-ACIHR at select AIIMS

Launch of Indian public health standards for Ayush healthcare facilities


Dr. Mandaviya addresses Governing Council Meeting of the ICMR
News | March 04, 2024

Dr. Mandaviya addresses Governing Council Meeting of the ICMR

ICMR’s budgetary allowance has increased by 4-fold in the past 10 years, showcasing our commitment towards Health Research


USFDA inspects Shilpa Medicare’s bio-analytical laboratory in Hyderabad
Drug Approval | March 02, 2024

USFDA inspects Shilpa Medicare’s bio-analytical laboratory in Hyderabad

This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently


Warren Remedies commences commercial production of oral care products
News | March 02, 2024

Warren Remedies commences commercial production of oral care products

The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra


Cipla incorporates JV company in USA
News | March 02, 2024

Cipla incorporates JV company in USA

Cipla completes transfer of Generics Business Undertaking


Cabinet approves post of director for National Institute for One Health
Policy | March 02, 2024

Cabinet approves post of director for National Institute for One Health

The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness


Pfizer Oncology hosts innovation day
News | March 01, 2024

Pfizer Oncology hosts innovation day

Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth


Suven announces merger of Cohance Lifesciences
News | March 01, 2024

Suven announces merger of Cohance Lifesciences

The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals